Physician profile
Devon L Evans
NPI 1518183532
$31,184.93
in general payments reported to CMS, 2019-2025
41 companies · $861 in 2025
The $861 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,658 · 2020: $8,480 · 2021: $13K · 2022: $2,298 · 2023: $173 · 2024: $388 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378 · Education: $44.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.63 |
| Education | $44.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $27,296.38 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Reflexion Medical, INC. | $2,159.80 | 2022 | |
| Daiichi Sankyo INC. | $193.97 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $186.23 | 2019-2023 | Imbruvica |
| Abbvie INC. | $176.43 | 2024-2025 | |
| Janssen Biotech, INC. | $172.61 | 2019-2025 | Erleada |
| Boston Scientific Corporation | $115.92 | 2023 | Axios |
| Novartis Pharmaceuticals Corporation | $71.48 | 2019-2025 | |
| Asd Specialty Healthcare, LLC | $56.42 | 2025 | |
| Pfizer INC. | $50.06 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $47.69 | 2025 | Opdivo |
| Astellas Pharma US INC | $47.07 | 2024-2025 | Vyloy, Padcev |
| Janssen Pharmaceuticals, INC | $44.00 | 2024 | Rybrevant |
| Incyte Corporation | $43.57 | 2021 | |
| Novocure INC. | $40.55 | 2025 | Optune Lua (Novottf-200t) |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $39.73 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $37.17 | 2025 | Keytruda |
| Seagen INC. | $32.18 | 2019-2021 | |
| Lilly USA, LLC | $26.88 | 2019 | |
| Exelixis INC. | $26.28 | 2019-2020 | |
| Amgen INC. | $24.41 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $23.36 | 2025 | Libtayo |
| Sobi, INC | $20.85 | 2025 | |
| Beone Medicines USA, INC. | $20.19 | 2025 | Tevimbra |
| Alnylam Pharmaceuticals INC. | $20.14 | 2025 | Givlaari |
| Dova Pharmaceuticals | $20.08 | 2019 | |
| Eisai INC. | $19.49 | 2025 | |
| Caris Mpi, INC. | $19.13 | 2025 | Mi Cancer Seek |
| Tolmar, INC. | $18.18 | 2025 | |
| Genentech USA, INC. | $17.60 | 2019 | |
| Kyowa Kirin, INC. | $17.52 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.50 | 2019 | |
| Emd Serono, INC. | $15.33 | 2025 | |
| Adc Therapeutics America, INC. | $15.07 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.73 | 2019 | |
| Acrotech Biopharma INC. | $12.52 | 2022 | |
| Celgene Corporation | $12.49 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.